10th Meeting of the European Forum on Antiphospholipid Antibodies

FACULTY OF MEDICINE
NANCY
FRANCE

www.apsnancy.com
Dear Members of the Forum,

All our team is thrilled to welcome you to the 10th Meeting of the European Forum on Antiphospholipid Antibodies.

This Forum meeting is the best place for the European clinicians and scientists involved in the field of APS to meet and strengthen current or future collaborations.

Furthermore, state of the art lectures as well as satellite symposiums are in the program.

Nancy is the capital of the artistic movement Art Nouveau that flourished in Nancy and across Europe from the late 19th century. Its influence is particularly visible in Nancy architecture. We will be delighted to invite you to a very special congress dinner which will take place in the Fine Arts Museum located in the Stanislas square inscribed on the UNESCO World Heritage List.

Sincerely yours,

Dr Jessie Risse,
Pr Stéphane Zuily
and Pr Denis Wahl
on behalf of the organizing committee
THURSDAY, APRIL 27

09.00 REGISTRATION AND WELCOME COFFEE

09.45 INTRODUCTION
M. Braun, Dean of Nancy Medical School
M. Claudon, CME President Nancy Academic Hospital
R. Cervera, General Coordinator
D. Wahl, S. Zuily

10.15 - 11.40 | NEW STUDIES: PRESENTATION AND DISCUSSION
Chairs: R. Cervera, D. Wahl

- 10.20 - 10.35
  Value of IgA anti $\beta_2$-GPI measurement in SLE
  A. Tincani, R. Kumar, L. Andreoli

- 10.35 - 10.50
  Circulating immune-complexes of IgG, IgA and IgM bound to $\beta_2$-GPI and acute thrombotic events
  D. Pérez, A. Serrano

- 10.50 - 11.05
  HIBISCUS: an international project as regards the effects of Hydroxychloroquine in preventing both thrombotic and obstetrical relapses
  C. Belizna

- 11.05 - 11.20
  DUCSDATA: a DUtch Consortium Study on Diagnostics And Treatment of Antiphospholipid syndrome
  M. Limper, R.T. Urbanus, H.G. Otten

- 11.20 - 11.40
  INSPIRE: the first Italian inception cohort of subjects positive for anti-phospholipid antibodies

11.40 - 13.00 | ABSTRACTS PRESENTATION
Chairs: L. Andreoli, P. de Groot

- 11.40 - 11.55
  Increased prothrombin conversion causes elevated thrombin generation in APS patients with prior thrombosis
  R. Kremers, S. Zuily, V. Regnault, D. Wahl, B. de Laat

- 11.55 - 12.10
  Thrombin activatable fibrinolysis inhibitor (TAFI) - a possible link between coagulation and complement activation in the APS
  G. Grosso

- 12.10 - 12.25
  Role of platelet activation in a mouse model of APS
  V. Proulle

- 12.25 - 12.40
  Lessons from the national antiphospholipid syndrome cohort: criteria and non-criteria manifestations
  L. Stojanovich

- 12.40 - 12.50
  aPS/PT antibodies: a clue to predict intrauterine growth restriction and preeclampsia in APS patients
  V. Canti

- 12.50 - 13.00
  Thrombotic manifestations in antiphospholipid antibody-related to virus infections

13.00 - 14.00 | LUNCH AND LATE BREAKING POSTER PRESENTATIONS

Refractory obstetrical antiphospholipid syndrome: features, treatment and outcome in a European multicentre retrospective study
A. Mekinian on behalf of the SNFMI and the European Forum on Antiphospholipid Antibodies
Non-conventional antiphospholipid antibodies in patients with clinical obstetrical APS: prevalence and pregnancies treatment efficacy
A. Mekinian, M.C. Bourrienne, L. Carbillon, A. Benbara, N. Abisror, S. Chollet-Martin, A. Tigaizin, F. Montestruc, O. Fain, P. Nicaise-Roland

Antibodies against S100A10 protein in antiphospholipid syndrome
V. Salle, J. Schmidt, A. Galmiche, M. Aubignat, C. Gourguechon, A. Dernoncourt, A. Smail, M.A. Delbarre, F. Pater, A. Brulé, Y.E. Herpe, P. Duhaut

14.00 - 14.30 | STATE OF THE ART LECTURE
The conformation of β2GPI and its diagnostic implications
B. de Laat

14.30 - 16.00 | SCIENTIFIC SESSION 1
NEW TESTS/NEW TECHNIQUES FOR ANTIPHOSPHOLIPID ASSAYS
Chairs: K. Devreese, B. de Laat

ABSTRACTS AND INVITED PRESENTATIONS

14.30 - 14.55
New automated measurement technologies for aPL testing
K. Devreese

14.55 - 15.06
A thrombin generation-based assay to distinguish anti-β2-glycoprotein I and anti-prothrombin antibodies: paving the way to a better thrombotic risk assessment in patients with antiphospholipid syndrome
W. Chayoua et al.

15.05 - 15.20
Recommendations from the ISTH-SSC for testing aPL with solid phase assays
K. Devreese

15.20 - 15.30
Antiphospholipid antibody titer stability after repeated freeze-thaw cycle: Solid as a Rock
K. Maelegheer, M. Luypaert, K. Devreese

15.30 - 15.40
APSdb: a database for efficient computing of antiphospholipid positivity profiles from laboratory records
M.D. Devignes, M. Smail-Tabbone, A. Hervé, S. Zuily, D. Wahl, J. Devignes

15.40 - 15.50
Usefulness of the non-conventional antiphospholipid antibodies in the diagnostics of APS
E. Litvinova, L. Darnige, Y. Burnel, M.A. Dragon-Durey

15.50 - 16.00
Anti-domain I-β2Glycoprotein I antibodies in antiphospholipid antibody carriers

16.00 - 16.30 | COFFEE BREAK

16.30 - 18.00 | SCIENTIFIC SESSION 2
OBSTETRICAL APS
Chairs: A. Ruffatti, J.C. Gris, O. Morel

ABSTRACTS PRESENTATIONS

16.30 - 16.45
A survey of the European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS)
E. Esteve-Valverde for the EUROAPS Study Group

16.45 - 17.00
Prevalence of antiphospholipid antibodies in pregnant women at the time of preeclampsia detection
B. Grand, A. Avigliano, M. Gonzalez Alcántara, L. Voto

17.00 - 17.15
Additional treatments combined with conventional therapies for high risk obstetric primary antiphospholipid syndrome: An international multicentre retrospective study
A. Ruffatti et al.
Effect of adjusted doses of heparin and switch therapy on pregnancy outcome in primary antiphospholipid syndrome. A prospective cohort management study

FORUM PROJECTS UPDATE

The obstetric risk and the effect of treatment in women with low titer anti-phospholipid antibodies

18.00 - 19.00 | SATELLITE SYMPOSIUM: NEW ANTICOAGULANT STRATEGIES FOR THROMBOSIS PREVENTION
Chairs: V. Eschwege, S. Zuily

DOAC studies in VTE
S. Zuily

Which lessons from DOAC studies could apply to APS?
A. Delluc

AstroAPS (video presentation)
S. Woller

Primary prophylaxis of thrombosis: new perspectives?
L. Arnaud

19:30 - 23:30 | CONGRESS DINNER

FRIDAY, APRIL 28

08.30 - 9.00 | STATE OF THE ART LECTURE
Pathophysiology of APS
P. de Groot

09.15 - 10.15 | SCIENTIFIC SESSION 3
DOACs in APS
Chairs: H. Cohen, V. Pengo

09.15 - 09.30
RAPS Study
H. Cohen

09.30 - 9.45
TRAPS Trial
V. Pengo

09.45 - 10.00
Review of literature data
S. Zuily

10.00 - 10.10
Direct thrombin inhibitors in patients with antiphospholipid syndrome
M.A. Satybaldyeva, N.V. Seredavkina, L.N. Kashnikova, I.N. Gorskikh, E.L. Nasonov, T.M. Reshetnyak

10.10 - 10.15
Future of DOACs in APS
D. Wahl

10.15 - 10.45 | COFFEE BREAK

10.45 - 11.50 | SCIENTIFIC SESSION 4
NEW TARGETS / TREATMENTS
Chairs: P.L. Meroni, V. Regnault

10.45 - 11.05
TREM1: potential player in APS?
S. Gibot

11.05 - 11.20
High risk laboratory APS Syndrome
J. Swadzba

11.20 - 11.30
Rituximab in APS (excluding CAPS)
R. Cervera

11.30 - 11.50
Complement inhibition and mTOR inhibition: perspectives
G. Canaud

11.50 - 12.20 | STATE OF THE ART LECTURE
Catastrophic antiphospholipid syndrome: Lessons from the “CAPS registry” and the “PRECISEADS project”
R. Cervera
12.30 - 13.30 | SATELLITE SYMPOSIUM INOVA UNMET NEEDS IN APS: VALUE OF THE NEW ANTI-PHOSPHOLIPID ANTIBODY TESTING
Chair: D. Wahl

- 12.30 - 12.50
 ß, Glycoprotein 1 Domain 1 in the assessment of thrombosis risk in APS
V. Pengo

- 12.50 - 13.10
The detection of anti-PS/PT antibodies in routine
L. Bertolaccini

- 13.10 - 13.30
Clinical utility for the Global APS Score (GAPSS)
S. Sciascia

13.30 - 14.15 | LUNCH AND POSTER VISIT
Endothelial dysfunction in antiphospholipid syndrome: myth or truth
N. Stanisavljevic

SLE: Quality of life in secondary antiphospholipid syndrome
G. Bogdanovic

Effects of Hydroxychloroquine for the prevention of miscarriages in obstetrical antiphospholipid syndrome
C. Belizna, C. Bertrand, C. Bertrand, L. Sentilhes

Arterial stiffness in APS and effects of treatment
C. Belizna, G. Desportes, A. Ghali, M. Hallab

Anti-factor-Xa-activity of selective and nonselective factor Xa inhibitors in patients with antiphospholipid syndrome and systemic lupus erythematosus
N.V. Seredavkina

Knowledge Management in Immunology with Content Curation
G.C. Faure, C. Andre-Botte, C. Kohler, D. Gerard, A.S. Lagneaux, M. De Carvalho Bittencourt

Use of TNF-α blockers in aPL-positive women with recurrent infertility (refractory cases)
E. Esteve-Valverde, R. Ferrer-Oliveras, J. Alijotas-Reig

Laboratory and clinical characteristics of isolated Lupus Anticoagulants

Catastrophic antiphospholipid syndrome (CAPS) in pregnancy: maternal and perinatal outcome in next pregnancies
B. Grand, G. Mainetti, A. Weinsziehr, M. Gonzalez Alcántara, L. Voto

Maternal and perinatal outcome in antiphospholipid syndrome (APS) with first line therapy (FLT) with low molecular weight heparin (LMWH) and low dose aspirin (LDA)
B. Grand, G. Mainetti, R. Zarate, M. Gonzalez Alcántara, L. Voto

14.30 - 16.00 | SCIENTIFIC SESSION 5
NEUROPSYCHIATRIC APS
Chairs: E. Hachulla, S. Sciascia

STATE OF THE ART LECTURES
- 14.30 - 15.00
Evidences of neuropsychiatric risk and of infra-clinic brain alterations in APS women with no thrombotic history
J.C. Gris

- 15.00 - 15.30
Cognitive manifestations of APS
C. Yelnik

ABSTRACT PRESENTATIONS
- 15.30 - 15.40
Possible relationship between valvular lesions and neurological manifestations in patients with primary and secondary antiphospholipid syndrome
A. Djokovic

- 15.40 - 15.50
Antiphospholipid Antibodies as a Risk Marker of Embolic Events in Infective Endocarditis

16.00 | CLOSING REMARKS
ORGANIZING COMMITTEE
@ NANCY ACADEMIC HOSPITAL / FACULTY OF MEDICINE
Vascular Medicine Division and Regional Competence Center for Rare Vascular and Auto-Immune Diseases
Rue du Morvan, 54511 Vandoeuvre-Lès-Nancy Cedex, France
Dr J. Risse, Pr S. Zuily, Pr D. Wahl

- Haematology: Dr V. Eschwège, Dr J. Devignes
- Immunology: Dr E. André-Botté
- Internal Medicine: Dr M. Heymonet, Dr S. Mohamed, Dr F. Maurier, Pr R. Jaussaud
- Obstetrics: Dr C. Lamy, Pr O. Morel
- Cardiovascular Research Unit (Inserm UMR_S 1116): Dr V. Regnault
- Association des Chefs de Service Hospitaliers du CHRU de Nancy (partnership): Mme Vauthier
- Nancy Faculty of Medicine, Lorraine University: E. Schal (logistics), L. Philis (communication), L. Phialy (graphic design)

INTERNATIONAL STEERING COMMITTEE
Pr P. de Groot (The Netherlands), Pr P.L. Meroni (Italy), Pr V. Pengo (Italy), Pr A. Ruffatti (Italy), Pr M. Khamashila (UK), Pr Y. Shoenfeld (Israël), Pr A. Tincani (Italy), Pr J. Swadzba (Poland), Pr J. Musial (Poland), Pr R. Cervera (Spain), Pr D. Wahl (France)

FRENCH SCIENTIFIC COMMITTEE
Pr Z. Amoura (Paris), Pr L. Arnaud (Strasbourg), Dr C. Belizna (Angers), Pr Y. Benhamou (Rouen), Pr A. Bura-Rivière (Toulouse), Pr J. Constans (Bordeaux), Pr N. Costedoat-Chalumeau (Paris), Dr L. Darnige (Paris), Pr A. Delluc (Brest), Dr E. Demaistre (Dijon), Pr J.C. Gris (Nimes), Pr F. Guillemin (Nancy), Pr E. Hachulla (Lille), Dr P. Lacolley (Nancy), Pr M. Lambert (Lille), Pr T. Martin (Strasbourg), Pr G. Pernod (Grenoble), Pr I. Quéré (Montpellier), Pr D. Stephan (Strasbourg)

SCIENTIFIC SUPPORT

INDUSTRY

Bristol-Myers Squibb
Pfizer

Inova Diagnostics
A Werfen Company

aspen
HYPHEN BioMed
DAYER
L E O

SANOFI
ThermoFisher Scientific

Stago
GlassSmithKane
SIEMENS
Theradag